| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
IC50: 3.9 μM (L3MBTL1), 3.2 μM (L3MBTL3), 15.6 μM (L3MBTL4)[1]
UNC926 hydrochloride targets L3MBTL1 (lethal(3)malignant brain tumor-like protein 1), a methyl-lysine reader domain protein. It binds to the MBT domain of L3MBTL1 with a Kd of 3.9 μM. The compound specifically inhibits L3MBTL1 rather than 53BP1, showing selectivity for L3MBTL1 over L3MBTL3 (IC50 = 3.2 μM) and L3MBTL4 (IC50 = 15.6 μM). |
|---|---|
| ln Vitro |
In addition, UNC926 shows no binding to CBX7 and a low micromolar affinity (IC50 of 3.2 μM) for the near homolog L3MBTL3 along with a decrease in affinity for the other MBT domains[1]. UNC926 (1–25 μM) prevents the 3xMBT domain from attaching to H4K20me1. In a dose-dependent way, UNC926 prevents L3MBTL13xMBT from interacting with the relevant histonepeptides. The fact that UNC926 has no effect on 53BP1's binding to H4K20me1 indicates that it is more selective for L3MBTL1 than 53BP1[1].
UNC926 hydrochloride inhibits L3MBTL1 with an IC50 of 3.9 μM. It selectively inhibits the L3MBTL13XMBT-H4K20me1 interaction in peptide pull-down assays. The compound shows selectivity for L3MBTL1 over other MBT domain-containing proteins. |
| ln Vivo |
In vivo activity data for UNC926 hydrochloride are limited. As an epigenetic reader domain inhibitor, it may have effects on gene expression and cellular processes. Further in vivo studies are needed to fully characterize its pharmacological effects.
|
| Enzyme Assay |
In vitro binding assays measure the affinity of UNC926 hydrochloride for L3MBTL1 using surface plasmon resonance or fluorescence polarization. Kd values are determined through direct binding measurements. Peptide pull-down assays confirm selective inhibition of L3MBTL1-H4K20me1 interaction.
|
| Cell Assay |
Cell-based assays measure the inhibition of L3MBTL1 function in cells. The compound's ability to modulate gene expression through L3MBTL1 inhibition is assessed. Selectivity is confirmed by showing no disruption of 53BP1 binding to H4K20me1.
|
| Animal Protocol |
In vivo efficacy is evaluated in animal models of L3MBTL1-related diseases. The compound's ability to modulate epigenetic regulation and cellular processes through L3MBTL1 inhibition is assessed. Further studies are needed to fully characterize its in vivo activity.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for UNC926 hydrochloride are limited. As a small molecule epigenetic reader domain inhibitor, it may have favorable oral bioavailability. Further pharmacokinetic studies are needed to determine its absorption, distribution, metabolism, and excretion properties.
|
| Toxicity/Toxicokinetics |
Preclinical toxicity data for UNC926 hydrochloride are limited. As an epigenetic reader domain inhibitor, it may have on-target effects related to gene expression modulation. Standard laboratory safety precautions should be followed. Further toxicological studies are needed for comprehensive safety assessment.
|
| References |
[1]. Herold JM, et al. Structure-activity relationships of methyl-lysine reader antagonists. MedChemComm. 2012;3(45):45-51.
|
| Additional Infomation |
UNC926 hydrochloride is a methyl-lysine reader domain inhibitor that specifically inhibits L3MBTL1 with an IC50 of 3.9 μM and a Kd of 3.9 μM. It selectively inhibits the L3MBTL1-H4K20me1 interaction without disrupting 53BP1 binding. The compound is a valuable research tool for studying L3MBTL1 biology and epigenetic regulation.
|
| Molecular Formula |
C16H22BRCLN2O
|
|---|---|
| Molecular Weight |
373.715682506561
|
| Exact Mass |
372.06
|
| CAS # |
1782573-49-2
|
| Related CAS # |
UNC926;1184136-10-4
|
| PubChem CID |
90488947
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
21
|
| Complexity |
335
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CCN(C1)C2CCN(CC2)C(=O)C3=CC(=CC=C3)Br.Cl
|
| InChi Key |
DPPMBBHOXQOMJI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H21BrN2O.ClH/c17-14-5-3-4-13(12-14)16(20)19-10-6-15(7-11-19)18-8-1-2-9-18;/h3-5,12,15H,1-2,6-11H2;1H
|
| Chemical Name |
(3-bromophenyl)-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6758 mL | 13.3790 mL | 26.7580 mL | |
| 5 mM | 0.5352 mL | 2.6758 mL | 5.3516 mL | |
| 10 mM | 0.2676 mL | 1.3379 mL | 2.6758 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
